Target Study Cost definition

Target Study Cost means the amount specified as such in item 6 of schedule 1 as varied under clauses 2.6, 9 or 10 from time to time.
Sample 1Sample 2Sample 3
Target Study Cost means the amount specified as such in item 5 of schedule 1 as varied under clause 8 or 9 from time to time. Terminated Other Segment Customer for a Customer’s Segment means a person that was an Other Segment Customer for that Customer’s Segment immediately prior to the termination of that person’s Other Funding Agreement under clause 6.5 of that person’s Other Funding Agreement. Termination Event for a Customer’s Segment means the termination, during a Month, of one or more Other Funding Agreements with one or more Terminated Other Segment Customers for that Customer’s Segment, under clause 6.5 of the Terminated Other Segment Customer’s Other Funding Agreement. Tier has the meaning given in item 1 of schedule 6.
Sample 1
Target Study Cost means the amount specified as such in item 4 of schedule 1 as varied under clauses 2.6, 8 or 9 from time to time. Terminated Other Customer means a person that was an Other Customer immediately prior to the termination of that person’s Other Funding Agreement under clause 6.5 of that person’s Other Funding Agreement. Termination Event means the termination, during a Month, of one or more Other Funding Agreements under clause 6.5 of the Other Funding Agreement. Tier has the meaning given in item 1 of schedule 6.
Sample 1

Examples of Target Study Cost in a sentence

  • Aurizon Network must notify All Study Funders of the variation to the Target Date and/or Target Study Cost (as applicable).

  • For example: “The enhancement to the rail infrastructure on the Alpha and Beta Systems in order to facilitate the transportation of coal to the approximately 25 Mtpa proposed coal terminal at Zenith.” A description or diagram clearly identifying the Expansion should be included on a transaction-by-transaction basis.] Schedule 3 Funding details Row / column number 2 As at the Commencement Date the Estimated Total Study Costs is equal to the Target Study Cost.

  • In this item 3 of schedule 6:Final Cost Measure or FCM means the amount (expressed as a percentage) calculated in accordance with the following formula:FSC TSCwhere:FSC = the total Study Costs for the Rail Study TSC = the Target Study Cost.

  • The Study Funder may in any instance where the Study Funder, acting reasonably, believes that Aurizon Network has delayed varying the Target Date or Target Study Cost in accordance with clause 10.1, give Aurizon Network a Dispute Notice which Disputes a variation to the Target Date and/or Target Study Cost (as applicable) specified in the notice given by Aurizon Network under clause 10.1(a)(ii).

  • Reporting Requirements and Process and Appeals for Part D Payment for Drugs for Beneficiaries Enrolled in Hospice.

  • For example: “The enhancement to the rail infrastructure on the Alpha and Beta Systems in order to facilitate the transportation of coal to the approximately 25 Mtpa proposed coal terminal at Zenith.” A description or diagram clearly identifying the Expansion should be included on a transaction-by-transaction basis.] Schedule 3‌Funding details Row / column number 2 As at the Commencement Date the Estimated Total Study Costs is equal to the Target Study Cost.

  • In this item 3 of schedule 6:Final Cost Measure or FCM means the amount (expressed as a percentage) calculated in accordance with the following formula: FSC TSCwhere: FSC=the total Study Costs for the Rail StudyTSC=the Target Study Cost.

  • Most DACA students are also granted work authorization; and if a student has work authorization, the student may be eligible to obtain a Social Security number.

  • In this item 3 of schedule 67:Final Cost Measure or FCM means the amount (expressed as a percentage) calculated in accordance with the following formula:FSC TSCwhere:FSC = the total Study Costs for the Rail Study TSC = the Target Study Cost.

  • The Study Funder may, if no agreement is reached within 20 Business Days after Aurizon Network convenes a meeting with All Study Funders under clause 9.5, give Aurizon Network a Dispute Notice which Disputes a variation to the Target Date and/or Target Study Cost (as applicable) specified in the notice given by Aurizon Network underclause 10.1(a)(ii).

Related to Target Study Cost

  • Development Costs means costs incurred to obtain access to reserves and to provide facilities for extracting, treating, gathering and storing the oil and gas from reserves. More specifically, development costs, including applicable operating costs of support equipment and facilities and other costs of development activities, are costs incurred to:

  • Development Cost means the total of all costs incurred in the completion of a Development excluding Developer Fee, operating deficit reserves, and total land cost as typically shown in the Development Cost line item on the development cost pro forma.

  • Phase I Study means a study in humans which provides for the first introduction into humans of a product, conducted in healthy volunteers or patients to obtain information on product safety, tolerability, pharmacological activity or pharmacokinetics, as more fully defined in 21 C.F.R. § 312.21(a) (or the non-United States equivalent thereof).

  • Phase II Study means a human clinical trial, for which the primary endpoints include a determination of dose ranges and/or a preliminary determination of efficacy in patients being studied as described in 21 C.F.R. § 312.21(b) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  • Phase III Study means a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. § 312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  • Development Expenses means, with respect to SAIL Developments as well as HOME Developments when the HOME Development is also at least partially financed with a MMRB Loan (as defined in rule Chapter 67-21, F.A.C.), usual and customary operating and financial costs, such as the compliance monitoring fee, the financial monitoring fee, replacement reserves, the servicing fee and the debt service reserves. As it relates to SAIL Developments as well as HOME Developments when the HOME Development is also at least partially financed with a MMRB Loan (as defined in rule Chapter 67-21, F.A.C.) and to the application of Development Cash Flow described in subsections 67-48.010(5) and (6), F.A.C., as it relates to SAIL Developments or in paragraph 67-48.020(3)(b), F.A.C., as it relates to HOME Developments, the term includes only those expenses disclosed in the operating pro forma on an annual basis included in the final credit underwriting report, as approved by the Board, and maximum of 20 percent Developer Fee per year.

  • Fully Burdened Manufacturing Cost means, with respect to any Licensed Product supplied by or on behalf of NVCR to Zai hereunder if such Licensed Product (or any precursor or intermediate thereof) is manufactured by a Third Party manufacturer [***].

  • Phase II Trial means a clinical trial of a Licensed Product on patients, including possibly pharmacokinetic and dose ranging studies, the principal purposes of which are to make a preliminary determination that such Licensed Product is safe for its intended use and to obtain sufficient information about such Licensed Product’s efficacy to permit the design of further clinical trials, and generally consistent with 21 CFR §312.21(b), or its successor regulation, or the equivalent in any foreign country.

  • Manufacturing Cost means [***].

  • Commercialization Costs means the sum of the following costs and expenses incurred by the Parties or their respective Affiliates, in Commercializing the Shared Products (and related Manufacturing activities) in the Territory, in each case, to the extent incurred in accordance with the Commercialization Plan and Commercialization Budget:

  • Phase II Clinical Study means a human clinical study of a product initiated to determine the safety and efficacy in the target patient population, as described 21 C.F.R. 312.21(b).

  • Phase III Trial means a human Clinical Trial of the Licensed Product, which trial is designed (a) to establish that the Licensed Product is safe and efficacious for its intended use; (b) to define warnings, precautions and adverse reactions that are associated with the Licensed Product in the dosage range to be prescribed; and (c) consistent with 21 CFR § 312.21(c).

  • Phase III Clinical Study means a trial involving administration of a Compound to sufficient numbers of human patients with the goal of establishing that the Compound is safe and efficacious for its intended use, to define warnings, precautions and adverse reactions that are associated with the drug or label expansion of such Compound, and to be considered as a pivotal study for submission of an NDA.

  • Phase I Trial means a clinical trial of a Licensed Product in human patients conducted primarily for the purpose of determining the safety, tolerability and preliminary activity of the Licensed Product, including, without limitation, for determining the maximum tolerated dose, or optimal dose. For purposes of this Agreement, a Phase I trial shall specifically exclude a study in healthy volunteers.

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • Phase I Clinical Study means, as to a particular Licensed Product, an initial clinical study in humans with the purpose of assessing the Licensed Product’s safety, tolerability, toxicity, pharmacokinetics or other pharmacological properties.

  • Phase 3 Study means a clinical study of an investigational product in patients that incorporates accepted endpoints for confirmation of statistical significance of efficacy and safety with the aim to obtain Regulatory Approval in any country as described in 21 C.F.R. 312.21(c), or a comparable Clinical Study prescribed by the relevant Regulatory Authority in a country other than the United States. The investigational product can be administered to patients as a single agent or in combination with other investigational or marketed agents [***]

  • Feasibility Study means the evaluation and analysis of the potential of a project, which aims at supporting the process of decision-making by objectively and rationally uncovering its strengths and weaknesses, opportunities and threats, as well as identifying the resources required to carry it through and ultimately its prospects for success;

  • Manufacturing Costs means the costs of Processing that generate Manufacturing Proceeds received by Grantor.

  • Phase IIb Clinical Trial means a clinical trial of a Product on sufficient numbers of patients that is designed to provide a preliminary determination of safety and efficacy of such Product in the target patient population over a range of doses and dose regimens.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Clinical Study means a Phase I Study, Phase II Study, Phase III Study, as applicable.

  • Development Plan has the meaning set forth in Section 3.2.

  • Phase II Clinical Trial means a controlled human clinical study that would satisfy the requirements of 21 CFR 312.21(b), conducted to study the effectiveness and establish the dose range of a Product for a particular Indication in patients with the disease or condition under study, including a Phase IIA Clinical Study or Phase IIB Clinical Study.

  • Research Project means a discrete scientific endeavor to answer a research question or a set of research questions related to medical marijuana and is required for a medical marijuana research license.

  • Development Activities means those activities which are normally undertaken for the development, construction, repair, renovation, rehabilitation or conversion of buildings for residential purposes, including the acquisition of property;